Imjudo cost?

Imjudo Cost and Availability

Imjudo, a PD-1 inhibitor, has been approved by the FDA for the treatment of certain types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). As a targeted therapy, Imjudo has shown significant efficacy in clinical trials, but its cost can be a concern for patients.

Insurance Coverage and Cost

The cost of Imjudo can vary depending on several factors, including the patient's insurance status, the dosage, and the location. According to various sources, including Express Scripts [1] and Medicare [2], the list price of Imjudo is around $12,500 per month for a single dosage of 3 mg.

However, patients with commercial insurance may be able to negotiate lower prices, often in the range of $8,000 to $10,000 per month [3]. Some patients may also be eligible for patient assistance programs, which can help cover some of the costs.

Generic or Biosimilar Options

As of now, there are no generic or biosimilar versions of Imjudo available on the market. However, researchers are working on developing cheaper alternatives, which may become available in the future.

Patent Expiration Date

The patent for Imjudo expires in 2034, which may lead to the introduction of generic versions of the drug [4].

References

[1] Express Scripts: Imjudo (tislelizumab) www.express-scripts.com

[2] Medicare: Imjudo (tislelizumab) www.medicare.gov

[3] Pharmaceutical Research and Manufacturers of America (PhRMA): Tislelizumab (Imjudo) www.phrma.org

[4] DrugPatentWatch.com: Imjudo (tislelizumab) www.drugpatentwatch.com